From: Design of Phase II cancer trials evaluating survival probabilities
Minimized | t 1 | C 1 | C 2 | I 1/Imax | EDA (%) | MDA(%) | ETSL (%) | MTSL (%) |
---|---|---|---|---|---|---|---|---|
ETSL | 1.8 | .137 | 1.164 | .31 | 2.65 (88) | 3.71 (124) | 3.10 (77) | 4.71 (118) |
 | 2.0 | .270 | 1.164 | .38 | 2.63 (88) | 3.59 (120) | 3.02 (76) | 4.59 (115) |
 | 2.2 @ | .375 | 1.172 | .46 | 2.65 (88) | 3.44 (115) | 3.00 (75) | 4.44 (111) |
 | 2.4 | .464 | 1.184 | .53 | 2.70 (90) | 3.32 (111) | 3.02 (75) | 4.32 (108) |
 | 2.6 | .550 | 1.198 | .61 | 2.78 (93) | 3.22 (107) | 3.07 (77) | 4.22 (105) |
EDA | 1.5 | -.313 | 1.223 | .25 | 2.66 (89) | 3.36 (112) | 3.28 (82) | 4.36 (109) |
 | 1.7 | -.125 | 1.218 | .31 | 2.60 (87) | 3.33 (111) | 3.15 (79) | 4.33 (108) |
 | 1.9 @ | .004 | 1.220 | .38 | 2.58 (86) | 3.27 (109) | 3.08 (77) | 4.27 (107) |
 | 2.1 | .109 | 1.227 | .46 | 2.60 (87) | 3.20 (107) | 3.06 (76) | 4.20 (105) |
 | 2.3 | .189 | 1.237 | .53 | 2.65 (88) | 3.13 (104) | 3.08 (77) | 4.13 (103) |